All together our data suggest that BCR/ABL-OOF is actively involved in the BCR/ABL signalling due to its specific oncogenic properties and it could provide additional targets for developing new drugs in order to eradicate CML stem cells. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.